Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CytomX Therapeutics (CTMX) Free Cash Flow (2016 - 2025)

Historic Free Cash Flow for CytomX Therapeutics (CTMX) over the last 12 years, with Q3 2025 value amounting to -$15.4 million.

  • CytomX Therapeutics' Free Cash Flow rose 2567.48% to -$15.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$72.4 million, marking a year-over-year increase of 1850.71%. This contributed to the annual value of -$86.5 million for FY2024, which is 5216.0% down from last year.
  • Latest data reveals that CytomX Therapeutics reported Free Cash Flow of -$15.4 million as of Q3 2025, which was up 2567.48% from -$15.8 million recorded in Q2 2025.
  • CytomX Therapeutics' 5-year Free Cash Flow high stood at $9.3 million for Q1 2023, and its period low was -$42.0 million during Q1 2022.
  • For the 5-year period, CytomX Therapeutics' Free Cash Flow averaged around -$22.6 million, with its median value being -$22.2 million (2023).
  • Within the past 5 years, the most significant YoY rise in CytomX Therapeutics' Free Cash Flow was 12211.94% (2023), while the steepest drop was 131136.51% (2023).
  • Over the past 5 years, CytomX Therapeutics' Free Cash Flow (Quarter) stood at -$31.4 million in 2021, then soared by 94.99% to -$1.6 million in 2022, then tumbled by 1311.37% to -$22.2 million in 2023, then rose by 10.08% to -$20.0 million in 2024, then rose by 22.85% to -$15.4 million in 2025.
  • Its Free Cash Flow stands at -$15.4 million for Q3 2025, versus -$15.8 million for Q2 2025 and -$21.2 million for Q1 2025.